Compare Constellation Energy Corporation (CEG) vs Summit Therapeutics Inc (SMMT) Price & Performance

CEG trades at $278.68, up 3.05% today, with a bullish technical outlook supported by moving averages and strong analyst sentiment. The company reported Q2 2026 EPS of $2.55, beating estimates, and raised 2026 guidance, driven by nuclear power demand and Calpine integration. Revenue growth is robust, with 2026 projections at $31.3B, and profitability metrics like ROE of 15.26% highlight efficient capital use.

The stock offers upside to the consensus price target of $332.13, with 70% of analysts rating it Buy. Key risks include execution of growth initiatives and market volatility, but strong cash flow and strategic positioning in AI-driven power demand support a positive outlook for investors.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.